Dr. Mato is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-2000
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2005 - 2008- University of Pennsylvania Health SystemResidency, Internal Medicine, 2002 - 2005
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2002
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2009 - 2025
NY State Medical License 2017 - 2025
NH State Medical License 2024 - 2024
NC State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
OK State Medical License 2020 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax Start of enrollment: 2020 May 13
- The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2020 Dec 03
- A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Start of enrollment: 2020 Dec 22
- Join now to see all
Publications & Presentations
PubMed
- Tolerability & long-term disease control by IGHV mutation status among CLL patients on ibrutinib arm of E1912.Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth Paietta, Susan M O'Brien M.D
Blood Advances. 2024-08-20 - 2 citationsHypertension treatment for patients receiving ibrutinib: a multicenter retrospective study.Laura Samples, Jenna Voutsinas, Bita Fakhri, Sirin Khajavian, Stephen Spurgeon
Blood Advances. 2024-05-14 - 28 citationsKinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.Skye Montoya, Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C Thompson
Science. 2024-02-02
Press Mentions
Nurix Therapeutics Presents Positive Clinical Results from Its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual MeetingDecember 12th, 2022- What’s Better for CLL: Sequential or Combination Therapy?October 4th, 2022
- Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate UpdateJuly 7th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
